Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Returns From Sanofi Consumer Expansion Could Point To More

Executive Summary

The French pharma's strategy of driving consumer health business growth by expanding the product lineup played out during the first quarter with the launch of OTC switch Xyzal Allergy and with further integration of OTC drug and vitamin brands recently acquired from Boehringer Ingelheim.

Advertisement

Related Content

Sanofi's Consumer Business Starts 2017 With 'Reassuring' Momentum
Xyzal Switch Extends Sanofi Into OTC 24-Hour Children's Antihistamine
Cialis Or Viagra Switch? Sanofi Survey, Pfizer Help Wanted Ad Could Be Signs
Sanofi CEO Sets Growth Target For Consumer Health Business

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS120546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel